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Abstract In 2005, the first national psoriasis survey in
Germany revealed large deficits in health care particularly in
patients with moderate to severe disease. The consecutive
goal was to improve health care for psoriasis countrywide.
For this, a large-scale national programwas initiated starting
with a comprehensive analysis of structures and processes of
care for psoriasis. Patient burden, economic impact and
barriers to care were systematically analyzed. In order to
optimize routine care, a S3 guideline, a set of outcomes
measures and treatment goals, were developed. Implemen-
tation was enforced by the German Psoriasis Networks
(PsoNet) connecting the most dedicated dermatologists. The
annual National Conference on Health Care in Psoriasis
established in 2009 consented National Health Care Goals in
Psoriasis 2010–2015 and defined a set of quality indicators,
which are monitored on a regular basis. Currently 28
regional networks including more than 800 dermatologists
are active. Between 2005 and 2014 7 out of 8 quality indi-
cators have markedly improved, and regional disparities
were resolved. e.g., mean PASI (Psoriasis Area Severity
Index) dropped from 11.4 to 8.1 and DLQI (Dermatology
Life Quality Index) from 8.6 to 5.9. A decade of experience
indicates that a coordinated nationwide psoriasis program
based on goal orientation can contribute to better quality of
care and optimized outcomes.
Keywords Psoriasis  Health Care Program  Quality of
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Introduction
Psoriasis is a chronic, genetically disposed immune disor-
der, which primarily manifests on the skin [23, 32]. Pso-
riasis can occur at every age and is accompanied by
inflammation, reddening and desquamation of the skin. In
Germany, 1-year-prevalence of psoriasis is about 2.5 % in
the population [12], and about 0.7 % in children [5],
resulting in approximately 2 million people affected by
psoriasis, including roughly 350,000 children. About
400,000 patients (25 %) [8] suffer from moderate to severe
forms and thus show a particularly high need for inter-
vention. Nail involvement in Germany affects about 40 %
[10] and psoriatic arthritis approximately 20 % of patients
consulting a dermatologist [45, 47]. The disease is
accompanied by an exceptionally high level of strain,
caused by physical symptoms such as feelings of tightness,
itching and pain, as well as psychosocial burden like
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stigmatization and chronic disease course [51, 52]. From a
societal perspective, there is also a considerable socio-
economic burden [53]. Chronic patient burden can result in
irreversible cumulative life course impairment [33]. The
disease burden and the patient’s life course impairment
trigger a high need for health care and require early
intervention in patients affected by disease. Thus, treatment
should follow patient needs on the one hand [21, 29] and
evidence-based guidelines on the other [34, 42].
Since the introduction of the first biological antipsoriatic
drugs in the year 2005, health infrastructure and quality of
health care have been the focus of intensive research in Ger-
many [16]. More than 30 nationwide projects have been
conductedwithin the last 10 years inorder to evaluate, explain
and improve health care for psoriasis. The outcomes of these
large-scale activities have been evaluated on a regular basis.
The intention of this publication is to summarize the
course of the national health care program for psoriasis in
Germany between 2005 and 2015 and provide recent out-
comes data on the goals achieved.
Research goals
The national program on psoriasis care was based
on the following questions
1. How is the need and the quality of health care for
psoriasis in Germany?
2. How can the quality of health care for psoriasis be
improved?
3. Which ways of action are to be used?
4. Which is the long-term-outcome of the national
psoriasis health care program assessed by quality
indicators?
Methods
The national psoriasis health care program included the
following steps (Fig. 1):
1. Measuring disease burden, needs, quality and out-
comes of health care for psoriasis
2. Definition of health care goals
3. Intervention program for improving health care
4. Evaluation program
Overall, the questions raised in the program were
addressed in 31 single studies (Table 1). Key results are
presented in this paper.
For avoiding bias from selection and from social
desiredness, different groups of individuals with psoriasis
in distinct settings were addressed. e.g., besides studies in
dermatology health care, surveys were conducted in the
German patient groups [35] via internet [3] and in a net-
work of German pharmacies [30, 31], all using the same set
of items.
In order to follow methodological standards, national
guidances on the methodology for quality of life assess-
ment [31], for epidemiological research [34] and for reg-
istry research [38] were developed.
Results
Measuring prevalence, disease burden, quality
and outcomes of health care for psoriasis
The series of projects aimed at characterizing the profile of
psoriasis health care and the needs for treatment. In order
to define the targets of health care research, a consensus
group was established 2005, including dermatologists,
health economists and health scientists from the German
Society of Dermatology (DDG), the Professional Associ-
ation of German Dermatologists (BVDD) and the German
Center for Health Services Research in Dermatology
(CVderm). Based on an internal consensus, the following
research topics were identified:
• Prevalence of psoriasis
• Patient relevance (patient burden)
• Clinical relevance (health care consumption)
• Economic impact
• Potential for prevention
• Quality of health care
• Guidelines (availability, use, compliance)
• Access to health care
• Benefits of treatments
• Efficiency of health care
• Gaps and under-/overprovision of care
• Barriers of health care
Identifying the prevalence of psoriasis in Germany
Epidemiology of psoriasis was the first key research topic
for better health care analysis and planning. In order to
control for selection bias and limitations of validity, dif-
ferent approaches were chosen, including:
• Analysis of sick fund (claims) data
• Population-based surveys
• Web-based surveys
The resulting prevalence rates were within the same
range with a mean prevalence in the sick fund analyses of
2.5 % [50], in the web surveys of 2.4 % [3]. The large-
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scale whole-body examinations by dermatologists on
90,880 individuals in more than 400 German companies
revealed a point prevalence of 2.1 % [7], fitting to the
estimated overall one-year-prevalence of 2.5 %.
Measuring disease burden
Patient burden from psoriasis in Germany was evaluated in
a series of large-scale cross-sectional studies. Significant
quality of life (QoL) losses were detected in the first studies
in 2005 [9]. e.g., mean DLQI in patients seeking treatment
in German dermatology practices was 8.6, mean PASI
12.0. 34.1 % of patients showed DLQI [10 indicating
relevant impairment of QoL. Only 33 % of patients with
severe disease received systemic treatments. Moreover,
there was large dissatisfaction with and a high perceived
burden from treatment. This therapeutic burden was iden-
tified as an important predictor of QoL impairment [22].
Costs of psoriasis
Two cost-of-illness studies revealed that psoriasis is accom-
panied by a high socio-economic burden [20]. Annual disease
costs in Germanywere estimated to be 9000 € for severe cases
and 4000–7000 € for mild tomoderate forms of psoriasis [53].
Causes for high direct costs are expenses for medication and
inpatient treatment; indirect costs arise from absence from
work and productivity losses. An additional 2400 € are initi-
ated by comorbid diseases. In Germany, compensation for
patients with statutory health insurance with mild psoriasis is
less than 500 €, with severe psoriasis approximately 7000 €.
Other cost determinants are intangible costs caused by loss of
QoL and psychological strain. Further data on patient self-
medication—invisible in the claims data—were derived from
a survey in the pharmacy networks. Substantial patient co-
payments of about 800 € per year were identified.
Identification of patient needs
In order to address more specific support for patients,
therapeutic needs were to be identified. Using the Patient
Benefit Index (PBI) [15], a broad spectrum of patient-rel-
evant therapeutic needs and potential benefits from treat-
ments were identified (Fig. 2) [21]. Psoriasis patients
named 21 out of 25 standardized benefit items to at least
50 %, including clearance of skin lesions, improvement of
itching and burning of skin, less time needed for treatment,
avoidance of treatment side effects and reduced physician
and clinic consultations. Such a broad spectrum of patient
needs required specific consideration in the translation of
guidelines into clinical practice. In particular, the choice of
therapy and the definition of treatment goals should take
individual patient preferences into consideration.
Definition of health care needs
Due to psoriasis prevalence, disease burden and socio-eco-
nomic impact, a high need for health care in psoriasis was
concluded. Additional demands arise from needs for early
detection and treatment of comorbidity: for example, a study
in2005 revealed thatmore than80 %ofpatientswithpsoriatic
arthritis had not yet been adequately diagnosed [47].
Fig. 1 Agenda of the National
Program for Psoriasis Health
Care 2005–2015
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Table 1 Series of Health Care Studies in the German National Psoriasis Program, conducted at the German Center for Health Services Research
in Dermatology (CVderm) in 2005 - 2015
CVderm 2005–2015 National health care goals addressed
1 2 3 4
Study Topic QoL PsA Com. Childr. HSR
PsoAdhere Identification and training of adherence in patients with psoriasis x
PsoAMNOG Evaluation of the German AMNOG drug assessment x
PsoArt Screening on psoriatic arthritis x
PsoBarrier Exploration of barriers for guideline-compliant health care in psoriasis and development of
strategies
x x x x
PsoBest The German Psoriasis Registry x x x
PsoBest-kid The German Psoriasis Registry, module for children x x x
PsoCare 1 ? 2 SHI health care study on children with psoriasis and atopic eczema x x x x
PsoCare 3 ? 4 SHI health care study on adults with psoriasis and atopic eczema x x x x
PsoCity Psoriasis in the population-based Hamburg City Health Study x x x x
PsoCom Standards and effectiveness of screening for comorbidity x
PsoComp Patient-relevant endpoints in psoriasis x x
PsoCort Use of corticosteroids in psoriasis: Metaanalysis x x
PsoCost Cost-of-illness and budget impact in psoriasis x x
PsoDrop Analysis of drug survival and persistance in real-world therapy for psoriasis (data from
PsoBest)
x x x x
PsoOdyssee Development and application of a comprehensive modeling system to predict and quantify
processes and outcomes on a national level
x x x x
PsoEpi Epidemiology of psoriasis in Germany x x
PsoEU Evaluation of the psoriasis health care structures, processes and quality in Europe: Survey
in 38 countries
x x x x x
PsoGoal Effectiveness of treatment goals in psoriasis x x x x x
PsoGuide Hurdles of guideline-compliant treatment of psoriasis in Germany x x x x
PsoHarm Methods for identifying patient harm in systemic treatment x x
PsoHead Prevalence of scalp psoriasis in Germany x x
PsoHealth 1–3 National health care studies for psoriasis 2005, 2007, 2014 x x
PsoKid Psoriasis health care in children x
PsoLife Long-term drug survival in psoriasis x x
PsoLong Characteristics of topical long-term treatment for psoriasis in German routine care x x
PsoMetrics Outcomes, measurement and treatment goals in psoriasis x
PsoMod Modelling of long-term course of psoriasis and psoriatic artrithis x x x x
PsoNet German Psoriasis Networks x x x
PsoPharm National health care studies for psoriasis in pharmacies 2009 x x x x
PsoPlus Benefits of membership in a psoriasis patient advocacy group: RCT x x
PsoPrefer Patient preferences in psoriasis therapy x x
PsoPRO Methodology of patient outcomes measurements x x x x
PsoRapid Optimising time to responds in psoriasis treatment x x x
PsoReal Health-care from the perspective of patient groups in Germany x x
PsoSat Patient satisfaction and treatment optimization x
PsoSpecial Benefits of psoriasis care in a specialized center x x
PsoTility Optimizing use of utility measures in psoriasis x x
PsoTop Topology of psoriasis x x x
PsoVac Vaccinations in systemic therapies for psoriasis x x x x
PsoWeb Web-based health care studies in psoriasis x x x x
PsoWork Impact of psoriasis on work productivity x x x
Numbers refer to health care goal
QoL improving Quality of Life (1)
PsA early detection of psoriaticarthritis (2)
Com. early detection of comorbidity (3)
Childr. improved quality of care for children (4)
HSR specific study on health services research (general goal)
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Association of psoriasis with obesity, diabetes mellitus, arte-
rial hypertension, dyslipidemia and autoimmune diseases was
shown in German population-based epidemiological studies
[12], confirming these associations as previously described in
other countries. Juvenile psoriasis patients already present
with higher prevalence of comorbidity such as diabetes and
obesity [9]. For this, a systematic screening and awareness
program including the different health care providers was
decided as national health care goal.
Measuring quality of health care and guideline compliance
(a) Definition and assessment of quality indicators
Quality measurement depends on standardized criteria. For
this, indicators for quality of health care in Germany based
on the national S3 guideline were developed in a consensus
process [44]. When applied in the first national study
PsoHealth1 conducted in 2005, there were striking deficits
in most indicators, which markedly improved in the second
national study PsoHealth2 2007 [13]. In spite of these
improvements, urgent need for further action remained,
which resulted in the definition of National Health Care
Goals in Psoriasis 2010–2015 [25].
For the evaluation of the national health care quality,
nationwide cross-sectional surveys in dermatology practices
and clinics were conducted [13]. In each survey, 50 % of the
centers derived from previous surveys and 50 % were ran-
domly selected from the list of dermatologists in Germany,
including about 3700 practice-based dermatologists and 119
clinical departments. Each center received a set of case report
forms for 20 patients, which needed to be included consecu-
tively. For each patient, a patient and a physician questionnaire
werefilled at the timeofpresentation in office.Descriptive data
analysis was conducted as described previously [13].
(b) Analysis of regional variations
Regional disparities which contradict expected out-
comes can be excellent indicators of health care quality.
For this, all national health care studies in the German
psoriasis program were analyzed by geographical vari-
ables. Large disparities in the prescription rates for sys-
temic and biologic drugs were found, although psoriasis
population, severity and clinical patterns do not vary sig-
nificantly [42]. Remarkably, areas with higher prescription
rates for systemic drugs also showed better average quality
of life and patient benefits from treatment than areas with
low use of systemic drugs.
(c) Analysis of treatment patterns in different specialties
Treatment patterns also depended on the specialty con-
sulted. The most striking finding was the widespread use of
systemic corticosteroids for psoriasis, especially by
internists and general practitioners (GPs), less often by
dermatologists [17]. Even when adjusted for comorbidity
requiring systemic steroids, these drugs were by far the
most frequently used systemic treatment for psoriasis in
Germany.
Evaluating access to psoriasis health care and treatment
variations
Knowledge of the proportion of patients with psoriasis
seeking health care in different specialties was crucial for
developing targeted health care interventions. Sick fund
analyses revealed that in Germany, psoriasis health care is
provided to an almost similar extent by dermatologists and
general practitioners (GP) (40–50 % each) [6]. Regarding
incidental patients, about 65 % start seeking a dermatologist
and 38 % aGP. A smaller percentage of adult patients is also
treated by other fields of profession, such as rheumatologists
in the case of psoriatic arthritis. In pediatric psoriasis, about
one-third of children and adolescents with psoriasis are cared
for by dermatologists, general practitioners and pediatricians
respectively [11]. Large discrepancies with regard to pre-
scribed therapies and quality of health care were observed
between the different fields of profession, e.g. pediatricians,
unlike dermatologists, rarely prescribed topical Vitamin D
analogues for mild psoriasis. And dermatologists, unlike
GPs and pediatricians, rarely used systemic steroids. Thus,
an obvious need for interprofessional communication on
treatment standards was identified.
Intervention program for improving health care
in psoriasis
Development and implementation of guidelines
In order to standardize treatment on a national level and to
provide maximum quality of care, a national evidence-
based S3 guideline on psoriasis treatment for adults was
developed and published in 2006 and updated in 2011 [39].
The developing process included patient participation.
Concordantly, a patient version of the guideline was pub-
lished in 2007. Due to the lack of a substantial number of
controlled psoriasis studies for children and adolescents, no
evidence-based guideline but a consensus paper was
developed for the age group below 18 years [54].
Patient empowerment
Up-to-date health care includes patient participation in the
process of therapeutic decisions (participatory medicine).
This concept requires sufficient information and the patient’s
understanding of the disease. In order to support patient
empowerment, the patient guideline on psoriasis treatment
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summarizes the content of the professional guideline in
appropriate language and is available free of cost. Moreover,
a systematic implementation of patient empowerment was
started in 2006 in collaboration with the German self-help
organization for psoriasis patients (DPB), including annual
conjoint meetings between patient groups and dermatolo-
gists [14].
National Conference on Health Care in Psoriasis
and National Health Care Goals in Psoriasis 2010–2015
Steering of health care and harmonization of nation-wide
health care goals are consented at the annual ‘‘National
Conference on Health Care in Psoriasis’’ in Germany [19].
Delegates of the conference are the executive boards of the
dermatological society and the professional association as
well as representatives of the regional psoriasis networks.
This conference passed the ‘‘National Health Care Goals in
Psoriasis 2010–2015’’ in 2009. Specifically, these goals are:
1. Patients with psoriasis have a good quality of life
2. Psoriatic arthritis is diagnosed timely
3. Comorbidity in psoriasis is diagnosed timely
4. Juvenile psoriasis is diagnosed and treated timely
These goals are a self-commitment of dermatologists for
the achievement of a measurable, good quality of care as a
general goal. All goals were differentiated in sub-goals
with a threshold to be achieved by 2015, e.g. the proportion
of patients with severe psoriasis receiving systemic drugs
could be increased from 33 % in 2005 to 65 % by 2015.
Fig. 2 Patient goals and needs from treatment in psoriasis
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Introduction of outcomes tools and treatment goals
One of the most important components of improved and
efficient health care is the implementation of tools for the
measurement of outcomes. Health care and treatment goals
can be set and used as standard only if it is possible to
validly measure them. Consequently, training and mea-
surement tools were developed, such as the ‘‘PASImeter’’
to measure the severity degree, the ‘‘PsAmeter’’ for
detection and assessment of psoriatic arthritis, and the
‘‘Comorbimeter’’ for early diagnosis of comorbid diseases.
Besides national guideline recommendations for appro-
priate psoriasis treatment, systematic treatment goals were
introduced by German experts [48], aiming at effective and
efficient therapy for individual patients. The core concept
is that therapeutic measures should only be continued as
long as there is prospect for disease improvement. More
stringent and efficient care is possible if treatment goals
related to specific time periods are set. This concept was
later transferred to a European consensus document [37,
48]. It could be shown that the use of treatment goals
obviously favors patient satisfaction and improves psoriasis
outcomes [46].
Development of regional psoriasis networks: PsoNet
For nationwide improvement of health care, 28 regional
psoriasis networks have been established since 2008 [1].
Within the initiative German Psoriasis Network (PsoNet),
dermatologists with special interest and expertise cooperate
efficiently. Core elements are their commitment to quali-
fied care according to the S3 guideline, their willingness to
cooperate in an interdisciplinary approach, and the partic-
ipation in health care research projects.
Consequently, the main PsoNet objective is the imple-
mentation of the National Health Care Goals in Psoriasis
2010–2015 [25] and thus quality of health care improve-
ment on the basis of the S3 guideline. Early detection of
psoriatic arthritis and other comorbidities by dermatolo-
gists are goals that can only be achieved by close cooper-
ation with other disciplines, with dermatologists as
important switch setters. The regional psoriasis networks
support the course through facilitation of cooperation, with
PsoNet standing for improved care through guideline-
compliant use of the entire spectrum of treatment options.
Health care goals, like the early detection of comorbidity in
psoriasis are also addressed by focus campaign, including a
consensus on comorbidity screening [43]. Every derma-
tologist and cooperating physician of other specialty
treating psoriasis or psoriatic comorbidities is invited to
join the German Psoriasis Network (PsoNet). Besides the
annual national meeting, cross-connection between the
regional networks and improved awareness is reached by a
biannual magazine called PsoNet Magazin [4] edited by the
presidents of the German dermatology societies, the Ger-
man self-help organization for psoriasis patients (DPB) and
the chair of PsoNet which provides internal up-to-date
information on psoriasis health care issues. Further infor-
mation is provided on a regular basis by the website,
including a search function for dermatologists specialized
in psoriasis [24].
Improved patient safety: The German Psoriasis Registry
PsoBest
In 2008, The German Psoriasis Registry PsoBest has
been established as a comprehensive patient registry for
monitoring the long-term course of systemic and bio-
logic therapies [18, 49]. Target parameters are drug
safety and effectiveness under routine conditions. While
short- and intermediate-term efficacy has been demon-
strated with a high level of evidence by a vast number of
clinical trials and summarized in the S3 treatment
guideline, data on effectiveness, safety and optimum
modalities in long-term treatment under everyday con-
ditions are lacking. This gap is bridged by PsoBest
which includes real-world patients at the start of sys-
temic or biologic treatment and monitors them irre-
spective of the treatment course for the subsequent
5 years. During this follow-up, data are collected with
standardized physician- and patient questionnaires alto-
gether 12 times in practices as well as 9 times in the
interim by mail. Scientific quality is ensured by methods
following international guidance; furthermore, the pro-
ject is supervised by an interdisciplinary scientific
advisory board in agreement with the dermatologic and
expert associations. PsoBest is part of the European
network of psoriasis registries [40]. At present, 691
dermatology practices and 64 hospital outpatient clinics
actively participate in PsoBest, reporting almost 4500
patients up to now with about 270 centers providing
90 % of data.
Identification of barriers
Restoring quality of life of patients, reducing psychosocial
burden and morbidity risks, and at the same time achieving
sufficient health care efficiency are the consented goals for
psoriasis treatment in Germany. Realization of these goals
is led by current research findings that are summarized in
the evidence-based S3 psoriasis treatment guideline. One
of the health care research objectives is to identify barriers
in guideline-compliant care and consequently to contribute
to their resolution [27]. Research is oriented along the
three-part barrier model with the components ‘‘external
factors’’, ‘‘physician’’, and ‘‘patient’’ (Fig. 3). All factors
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have facilitating as well as obstructing effects on barriers
and consequently, each of them contribute to quality of
health care.
Awareness program: World Psoriasis Day
In order to increase awareness for psoriasis as a widespread
disease and to support patient needs, the World Psoriasis
Day is held worldwide yearly on October 29th since 2005.
This day intends to emphasize the issues of 150 million
people affected by psoriasis worldwide. In Germany, most
regional psoriasis networks organize public events and are
available for media on this day which is widely announced
on a specific website [26].
Certification on quality in psoriasis care
In 2014, the German Society of Dermatologists (DDG) and
the Professional Association of German Dermatologists
(BVDD) decided to develop a certificate, which outlines
dermatologists to have a particularly high expertise in
psoriasis care. Quality is controlled by participation in the
PsoBest registry. Specific contracts and honoraria by the
payers are connected with this certificate.
Dissemination of health care data
For optimum improvement of quality of care, continuous
information of the health care decision makers and the
payers is crucial. In order to disseminate respective facts,
the book ‘‘Versorgung der Psoriasis in Deutschland: Fakten
2014’’(German Health Care on Psoriasis: Facts 2014) was
developed, summarizing all information on health care
forpsoriasis. Moreover, a multi-author special issue of the
most common German health political journal ‘‘Ge-
sellschaftspolitische Kommentare–gpk’’ (Societal Political
Comments) for the stakeholders in health politics was
issued, addressing to more than 6000 decision makers in
the national and regional parliaments, health care admin-
istrations, sick funds and further bodies.
Evaluation program for improvement of health care
in psoriasis
In order to verify the psoriasis health care program in
Germany, the central outcomes and quality indicators of
psoriasis care are recorded on a regular basis.
The last evaluation in 2013/2014 has revealed a substantial
increase in quality of health care compared to 2005 and 2007.
Fig. 3 Barriers to guideline-compliant psoriasis care
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7 out of 8 indicators significantly improved, and 2 reached the
level of the health care goals 2010–2015 prematurely
(Table 2) [36], e.g. mean PASI dropped from 11.4 (2005) to
10.1 (2007) and 8.1 (2013), mean DLQI decreased from 8.6
(2005) to 7.5 (2007) and 5.9 (2013). The proportion of patients
with PASI[20 declined from 17.8 (2005) to 11.6 (2007) and
9.2 (2013), the proportion of patients with DLQI[10 from
34.0 (2005) to 28.2 (2007) and 21.3 (2013). In the same period
the proportion of patients, who had received systematic
treatment for psoriasis in the previous 5 years increased from
32.9 % (2005) to 47.4 % (2007) and 59.5 % (2013) and
reached the national health care goal. Finally, there was also a
decrease in lost work days from 4.9 (2005) to 3.5 (2013).
Discussion
Psoriasis is a common chronic disease affecting all age groups
and leading to substantial patient burden [5, 8, 41]. There is
high need for health care, especially in patients withmoderate
to severe disease or significant comorbidity. In spite of this, in
Germany like inmany other countries there was a low level of
awareness and a marked lack of health care provision when
first systematic data were researched in 2005.
In order to better characterize health care for psoriasis
and to identify the specific needs for treatment in Germany,
a series of health care studies was conducted between 2005
and 2008, which showed the gaps and potential goals of
action [55]. The results of these first investigations trig-
gered a systematic national program for improving health
care in psoriasis, which included strong collaboration
between dermatologists and patients. Major elements were
the development of a S3 treatment guideline in 2006, the
implementation of regional psoriasis networks by derma-
tologists in 2008, the establishment of an annual national
psoriasis conference in 2009 and the definition of National
Health Care Goals in Psoriasis 2010–2015. At the patient
level, the initiatives for measuring disease, defining treat-
ment goals and turning to a more patient-centered treat-
ment approach were crucial. By cross-sectional health care
studies, the goal achievement was verified and specific
measures both on regional and national levels taken. To our
knowledge, this is the first such attempt in the field of
psoriasis.
The results of the recent health care study PsoHealth3
show that within the period between 2005 and 2014, large
nationwide improvements have been achieved with respect
to reducing disease severity and burden, improving quality
of life and decreasing indirect costs due to reduced work
productivity. Regional comparisons were very supportive
in identifying the need for action. Nevertheless, gaps in
health care provided by dermatologists remain and there
are still greater deficits in health care for psoriasis by GPs,
pediatricians, and internists. Thus, there is a need for
redefining health care goals for the period 2016–2020.
Regarding patient safety in systemic therapy, the pharma-
covigilance data from The German Psoriasis Registry
PsoBest indicate a high level of drug safety without any
unexpected safety signals to date [41].
On an international level, a higher level of awareness on
the need of better psoriasis health care has emerged as well.
For example, a European psoriasis petition was released in
2012 followed by the European White Paper published by
dermatology experts and patients with the demand for
improved quality of care [2, 28]. Such activities, in par-
ticular by patient advocacy groups, have supported the
resolution by the World Health Assembly (WHA) from
May 2014 [55]. With this initiative, the World Health
Organization (WHO) has confirmed the need for action
both on the level of awareness, fight against stigmatization
and better access to treatments in its member states. This
WHA decision has further encouraged patients,











n 1511 2009 1258
Mean PASI 11.4 10.1 8.1 \8.0 ?a
Mean DLQI 8.6 7.5 5.9 \6.0 ??b
% PASI[20 17.8 % 11.6 % 9.2 % \10 % ??
% DLQI[10 34.0 % 28.2 % 21.3 % \15 % ?
% With previous systemic treatment 32.9 % 47.3 % 59.5 % [65 % ?
% Hospital treatment (past 5 years) 26.9 % 20.1 % 20.1 % \15 % (?)c
Mean number of days absent from work 4.9 4.0 3.5 \3.0 ?
a ? = Major improvement
b ?? = Goal 2015 reached prematurely
c (?) = Minor improvement
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dermatologists and other health care professionals to claim
better treatment for patients in need.
A limitation of the national psoriasis health care pro-
gram is its main focus on improving quality of care by
dermatologists but not by other specialties. Although they
provide the largest proportion of health care for psoriasis in
the country [6], it has appeared that further quality
improvement programs need to be extended to other caring
groups, in particular GPs. A limitation of the evaluation
program is that there has not been a randomized controlled
study design for the evaluation of specific interventions and
the nationwide long-term health care outcomes. However,
nationwide health care interventions can hardly be subject
of a study design like in single clinical trials. Furthermore,
the effects on PASI and DLQI might results from a dif-
ferent selection of patients. In order to minimize this
potential confounder, a large number of randomly chosen
centers were recruited and consecutive patient inclusion
was mandatory.
Regardless of these potential limitations, such a
nationwide health care program based evidence-based
guidelines, structured care and goal orientation may be an
impulse for other health care settings and could be bene-
ficial also in other indications. A first transfer using expe-
rience with the psoriasis program was initiated in 2015
with the establishment of a national health care program on
skin cancer in Germany [21].
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